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Modulation of brain activation during executive
functioning in autism with citalopram
Robert H. Wichers 1,2, James L. Findon1, Auke Jelsma1,3, Vincent Giampietro 4, Vladimira Stoencheva2,
Dene M. Robertson1,2, Clodagh M. Murphy 1,2, Grainne McAlonan1,2, Christine Ecker5, Katya Rubia6,
Declan G. M. Murphy 1,2 and Eileen M. Daly1
Abstract
Adults with autism spectrum disorder (ASD) are frequently prescribed selective serotonin reuptake inhibitors (SSRIs).
However, there is limited evidence to support this practice. Therefore, it is crucial to understand the impact of SSRIs on
brain function abnormalities in ASD. It has been suggested that some core symptoms in ASD are underpinned by
deficits in executive functioning (EF). Hence, we investigated the role of the SSRI citalopram on EF networks in 19
right-handed adult males with ASD and 19 controls who did not differ in gender, age, IQ or handedness. We
performed pharmacological functional magnetic resonance imaging to compare brain activity during two EF tasks (of
response inhibition and sustained attention) after an acute dose of 20 mg citalopram or placebo using a randomised,
double-blind, crossover design. Under placebo condition, individuals with ASD had abnormal brain activation in
response inhibition regions, including inferior frontal, precentral and postcentral cortices and cerebellum. During
sustained attention, individuals with ASD had abnormal brain activation in middle temporal cortex and (pre)cuneus.
After citalopram administration, abnormal brain activation in inferior frontal cortex was ‘normalised’ and most of the
other brain functional differences were ‘abolished’. Also, within ASD, the degree of responsivity in inferior frontal and
postcentral cortices to SSRI challenge was related to plasma serotonin levels. These findings suggest that citalopram
can ‘normalise’ atypical brain activation during EF in ASD. Future trials should investigate whether this shift in the
biology of ASD is maintained after prolonged citalopram treatment, and if peripheral measures of serotonin predict
treatment response.
Introduction
Autism spectrum disorder (ASD) is a neurodevelop-
mental condition that is characterised by social commu-
nication deficits and repetitive or stereotypical
behaviours1. It has been estimated that 29% of individuals
with ASD in the UK are prescribed psychotropic medi-
cations2. Antidepressants, mainly selective serotonin
reuptake inhibitors (SSRIs), are prescribed in 6% of people
with ASD in the UK2, and are the fourth most commonly
prescribed psychotropic drugs worldwide in adults with
ASD3. SSRIs are normally prescribed for mood and
anxiety disorders, which are highly prevalent (26–57% and
29–54%, respectively4–7) in ASD. For this practice is, to
the best of our knowledge, currently no available evi-
dence. There is, however, a small body of work suggesting
that SSRIs are effective in treating core symptoms in
adults with ASD. For instance, two studies of fluoxetine
reported significant reductions in repetitive behaviours8,9.
One study of fluvoxamine in adults with ASD also
reported a reduction in repetitive behaviours as well as
improvement of social communication10. However, these
studies included limited sample sizes and the reported
benefits were small in comparison to placebo. This
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indicates that clinical trials are needed to further inves-
tigate the effectiveness of SSRIs in adults with ASD,
especially as there are currently no pharmacological
treatments approved by the Food & Drug Administration
(FDA) for treating core symptoms. However, clinical trials
have become increasingly expensive11, most trials in
neuropsychiatric disorders fail, and so industry is invest-
ing less in neuroscience. Therefore, it is crucial that we
first provide ‘proof of concept’ that potential treatments
(e.g. SSRIs) can impact on abnormalities in brain func-
tions associated with core symptoms. Moreover, it has
been proposed that core symptoms are partially under-
pinned by deficits in executive functioning (EF) in
ASD12,13. Therefore, EF networks may provide novel
treatment targets and/or an early ‘read out’ of potential
efficacy.
Executive functioning comprises a range of cognitive
processes that are required when concentrating and
paying and/or switching attention14. Individuals with ASD
have been reported to have difficulties in performing EF
tasks. For example, poorer performance has been reported
in adults with ASD compared to controls during perfor-
mance of a response inhibition task15 and in children and
adults during performance of sustained attention
tasks16,17. Additionally, functional MRI studies have
demonstrated abnormal brain activation in children and
adults with ASD as compared to controls during response
inhibition18,19 and sustained attention tasks16,20. The
biological basis of this is poorly understood but may
include the serotonergic system, which is involved in
motor inhibition21 as well as sustained attention22. For
example, it has been reported in typical developing
populations that increasing brain 5-HT with SSRIs can
improve performance of a response inhibition task23.
Studies of sustained attention have also implicated 5-HT
—possibly through its dampening effect on noradrenaline,
dopamine and acetylcholine, which all play a key role in
maintaining high levels of vigilance24,25. This is in line
with evidence that both single and repeated dosages of
SSRIs impair performance during sustained attention
tasks in neurotypical populations22,25–27.
The serotonergic system is crucial to brain development
in embryonic life28 and is also implicated in the patho-
physiology of ASD. For example, the serotonin (5-HT)
transporter gene (SLC6A4) has been associated with
ASD29, hyperserotonemia is frequently reported in chil-
dren and adults30 and a decrease in density of 5-HT
receptors31 and the 5-HT transporter32 has been observed
in adults with ASD. In addition, we previously demon-
strated that, in ASD boys, abnormalities in the activation
of prefrontal regions during EF tasks (of motor inhibition,
cognitive flexibility and working memory) were ‘normal-
ised’ after a single dose of fluoxetine18,33,34. However, to
date no one has investigated the effect of an SSRI on EF
networks in adults with ASD. In addition, no one has
tested whether shifting of brain activation after SSRI
administration is related to biological serotonergic mar-
kers, including peripheral 5-HT levels. If successful, this
may help provide a rationale for further testing to deter-
mine if modulation of brain function is maintained by
longer-term treatment.
Therefore, we tested the effect of the SSRI citalopram
on two EF networks (of response inhibition and sustained
attention) in adults with ASD using pharmacological
functional Magnetic Resonance Imaging (fMRI). Based on
our previous work18,33,34, we hypothesised that citalopram
would modulate abnormal brain activation during EF
towards control levels. In addition, we related peripheral
5-HT levels to change in brain activation after citalopram
administration. Our subsidiary hypothesis was that degree
of responsivity to citalopram would be associated with
increased peripheral 5-HT levels.
Materials and methods
Participants
Nineteen male, right-handed adults with ASD and 19
typically developed (TD) control participants were inclu-
ded in the study (age: TD mean= 27, SD= 9, ASD mean
= 30, SD= 11). Two TD and 2 ASD cases were excluded
from the Go/No-Go task due to significant head move-
ment. The sample size was chosen based on results from
our prior experiments targeting 5-HT modulation using
both acute tryptophan depletion35,36, which were suc-
cessful in detecting group differences in BOLD response
with sample sizes of n= 14. This implies an effects size
(expressed in Cohen’s d) in excess of 1.235,36. Exclusion
criteria included medical disorders that could influence
cognitive performance, major mental illnesses other than
ASD, genetic disorders associated with ASD, alcohol or
substance dependence or taking any medication affecting
the serotonergic system (e.g. antidepressants, anti-
psychotics, benzodiazepines or mood stabilisers). ASD
diagnosis was made by a consultant psychiatrists using
ICD-10 research criteria1 and confirmed using the Autism
Diagnostic Interview-Revised (ADI-R)37 (Communica-
tion: mean= 20, SD= 7, Social Interaction: mean= 16,
SD= 7, Repetitive Behaviour: mean= 5, SD= 2) if an
informant was available. Current autistic symptoms were
measured by the Autism Diagnostic Observation Schedule
(ADOS)38 (Communication: mean= 3, SD= 2, Social
Interaction: mean= 6, SD= 2). Intelligence was measured
by the Wechsler Abbreviated Scale of Intelligence test
(WASI)39 (TD mean= 115, SD= 10, ASD mean= 113,
SD= 14). All participants completed baseline self-
reported questionnaires of autistic traits (Autism-Spec-
trum Quotient)40, obsessionality (Obsessive-Compulsive
Inventory-Revised)41, and current symptoms of ADHD
(Barkley Adult ADHD Rating Scale—IV)42. A brief
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interview was conducted by a medical doctor to assess
symptoms of anxiety and depression using The Hamilton
Rating Scales for Depression43 and Anxiety44. All parti-
cipants gave written, informed consent after receiving a
complete description of the study. The study was ethically
approved by the Stanmore Ethics Committee.
Platelet rich plasma serotonin
In order to assess the peripheral serotonergic status of
each participant, 7 ml of blood was collected in an
anticoagulated EDTA tube, on one occasion, prior to drug
administration. One tube was centrifuged at 140 × g for
25 minutes at 4 °C within 20 min after venipuncture.
Centrifugation usually yielded ~3–4ml of supernatant
(platelet-rich plasma, PRP). A 1ml aliquot of PRP was
transferred into a 1.5 ml Eppendorf tube, frozen imme-
diately, and stored at −80 °C until performance of
Enzyme-Linked Immunosorbent Assay (ELISA) analysis
of plasma 5-HT levels.
Citalopram administration procedure
For the fMRI scans participants were required to com-
plete two scanning sessions: one after receiving a single
dose of 20 mg of encapsulated citalopram and one after
receiving a dose of encapsulated placebo (ascorbic acid),
in a randomised, double-blind, crossover design. A list of
blinding numbers were produced independently and
passed directly to the pharmacy in the outpatient
department of the Maudsley Hospital using a compu-
terised random number generator and using a blocked
randomisation which allowed us to analyse our data at
several time points in the study. The pharmacy used these
numbers to blind each dose (placebo; encapsulated
ascorbic acid/medication; citalopram) as they are manu-
factured. Both subject and researcher(s) were blind to
dosing during the study. The randomisation and encap-
sulation was conducted according to Good Medical
Practice and in accordance with CONSORT & SPIRIT
guidelines. Each dose was given to the participant 3 h
prior to scanning, as citalopram reaches its peak plasma
level after approximately 3 h45. There was a minimum of
eight days between the scans to allow for complete
washout of the drug (t½= 36 h; washout= 5*t½=
7.5 days). All participants received a screening by a
medical doctor before and after the administration of
both doses.
Visual analogue scale
All participants administered self-reported visual
analogue scale questionnaires prior to drug administra-
tion and after the fMRI-scan. Symptoms potentially
associated with citalopram were measured, including
palpitations, nausea, dizziness, attentiveness, anxiety and
irritability.
Go/No-Go inhibition fMRI task
In order to probe the brain’s response inhibition system,
a Go/No-Go task was performed during each scanning
session19,46. During this task, either a motor response on a
button box to Go signals is required or the inhibition of
this response to No-Go signals. Arrows pointing to either
the left or right side appear on the screen. The subject has
to press the left or right response button on a diamond-
shaped keypad as response. Infrequently (12%), arrows
pointing to the top (No-Go signals) appear. Subjects have
to inhibit their motor response to these stimuli. In 12% of
trials, slightly slanted arrows pointing left or right appear
and subjects have to treat them the same way as Go sig-
nals. In order to control for the attentional oddball effect
due to the low frequency occurrence of No-Go trials, No-
Go trials were compared to successful oddball trials19,46.
Sustained attention fMRI task
In order to probe the brain’s sustained attention net-
work system, the sustained attention task was performed
during each scanning session16,20,47. Subjects need to
respond via a right hand button response as quickly as
possible, and within 1 s, to the appearance of a visual
timer counting up in milliseconds. When they press the
button to the counter the counter will show their reaction
time as it counts milliseconds. They are instructed to
press as soon as they see the counter. The visual stimuli
appear either after short, predictable consecutive delays of
0.5 s (260 stimuli in total), in series of 3–5 consecutive
stimuli or after unpredictable time delays of 2, 5 or 8 s (20
each), which are pseudo-randomly interspersed into the
blocks of 3–5 delays of 0.5 s. The long, infrequent,
unpredictable delays place a higher load on sustained
attention, as subjects have to wait for them to occur and
they do not know the exact time of when they will occur
(2, 5 or 8 s) whereas the short, predictable 0.5 s delays
which appear in a row are typically anticipated. Partici-
pants learn to estimate the 0.5 s and know that there will
be several stimuli appearing in a row48, placing a higher
demand on sensorimotor synchronisation20. Activation to
the longest delay (8 s) that placed the highest load on
sustained attention, and showed most activation, was
compared to brain activation during the short delays
(0.5 s) (Supplementary Table 1).
We have shown consistently with this task that sus-
tained attention networks are activated during the long
delays relative to the short delays and that, with longer
delays, there is progressively increasing activation from 2 s
to 8 s16,20,47.
Characteristics and performance statistical analysis
Statistical tests were performed using SPSS software
(v23.0). T-tests were used to compare baseline char-
acteristics between groups and multivariate analysis of
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variance (MANOVA) to determine any differences in
performance and visual analogue scale outcome measures
between group and drug conditions. Analysis of variance
(ANOVA) was used to compare largest displacement in
head movement between group and drug conditions.
For the Go/No-Go task the performance measures
include: probability of inhibition (main inhibitory mea-
sure), mean reaction time to the Go signal (motor
execution measure) and mean reaction time to the odd-
ball signal. For the sustained attention task the perfor-
mance measures include: coefficient of variation
(variation in reaction time during performance of the task
adjusted for reaction time, i.e. standard deviation of
reaction time divided by reaction time), mean reaction
time, premature responses and omission errors.
fMRI image acquisition
All participants were scanned on a 3-Tesla General
Electric Signa HD x Twinspeed scanner (Milwaukee,
Wisc.), fitted with a quadrature birdcage head coil. For the
fMRI, we acquired 260 (Go/No-Go task) and 480 (sus-
tained attention task) T2*-weighted volumes on 37 (Go/
No-Go task) and 31 (sustained attention task) non-adjacent
planes parallel to the anterior-posterior commissure (TE=
30ms, TR= 1.8 s (Go/No-Go task); 1.5 s (sustained atten-
tion task), flip angle= 73° (Go/No-Go task); 68° (sustained
attention task), slice thickness= 3.0mm, in-plane voxel-
size= 3.75mm2, slice gap= 0.7mm (Go/No-Go task);
1.4mm (sustained attention task); matrix size= 64 × 64
voxels). Also, a high resolution gradient echo structural
scan, on which activation maps were superimposed, was
sagitally acquired to be used during normalisation of the
fMRI data into Talairach space. (TR= 3 s, TE= 30ms,
43 slices, flip angle= 90°, slice gap= 0.3 mm, slice thick-
ness= 3.0mm, matrix size= 128 × 128 voxels).
fMRI image analysis
The fMRI data was analysed using XBAM (version 4)
software developed at the Institute of Psychiatry, Psy-
chology and Neuroscience49. This method is decribed in
brief in this section and in more detail in the supple-
mentary material section. This non-parametric approach
minimises assumptions involved in image processing and
has been previously described36. Within each run, every
volume was realigned to the mean of all the images in the
run and then smoothed using a Gaussian filter (full-width
at half-maximum 8.8 mm). Using a wavelet-based
resampling method for functional MRI data, a time ser-
ies analysis was conducted on each individual subject, in
order to compute a sum of squares (SSQ) ratio reflecting
the BOLD effect. SSQ ratio maps were transformed into
standard stereotactic space50 using a two-stage warping
procedure49. First, an average image intensity map for
each individual was computed. We then determined the
transformations required to map this image to the
structural scan for each individual and then from ‘struc-
tural space’ to the Talairach template by maximising the
correlation between the images at each stage. The SSQ
ratios were then transformed into Talairach space using
these same transformations. Group brain activation maps
were computed for each drug condition with hypothesis
testing performed at both the voxel and the cluster level.
Using data-driven, permutation-based methods, with
minimal distributional assumptions, we performed time
series analyses for group maps and inter-group random
permutation for within/between-group ANOVAs to
compute the distribution of the SSQ ratio under the
relevant null distribution hypothesis. Thresholding to the
required level of significance was then performed using a
two-stage process: first at a voxel-wise p-value of 0.05,
followed by grouping the supra-threshold voxels into 3D
clusters and testing their significance against a null dis-
tribution of clusters occurring by chance in the permuted
data. A group brain activation map was produced for each
group (TD, ASD) and medication (placebo, citalopram)
status. We conducted all ANOVA analyses with p < 0.05
for voxel level and with p < 0.02 at cluster level. This
resulted in less than one false positive cluster per map for
the sustained attention task and three potentially false
positive clusters for the Go/No-Go task.
Between group analysis of variance
A main effect of group analysis was conducted for the
placebo condition for each task. To investigate whether
brain activation differences in the ASD group relative to the
control group under placebo changed after citalopram dose
in ASD, a main effect of group analysis was conducted in
regions showing a main effect of group under placebo, but
now comparing the control group on placebo with the ASD
group on citalopram, to test for potential ‘normalisation’
effects. Furthermore, a within ASD effect of drug analysis
was conducted, in regions showing a main effect of group,
to investigate whether the degree of change in activation in
ASD following citalopram was significant (‘normalised’).
Group x medication interaction analysis of variance
A two-group (TD, ASD) by two-drug status (placebo,
citalopram) factorial repeated-measures ANOVA was
conducted for each task. In the groupxdrug status inter-
actions the effect on the BOLD response in brain regions
is different in each group depending on drug status. The
cluster-level threshold was adjusted to p < 0.02, resulting
in less than one false-positive cluster per map.
Correlations between symptomatology, serotonin and
change in functional activations
Pearson’s correlations were conducted in XBAM to
investigate any associations between core symptoms
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(measured by the ADI-R and ADOS), associated symp-
toms of ADHD, anxiety, depression and obsessionality
(measured by the BAARS-IV, HAM-A, HAM-D and OCI-
R), PRP 5-HT levels and difference in BOLD response
between groups under the placebo condition or change
between citalopram and placebo conditions
(citalopram–placebo), in regions showing a main effect of
group during placebo, during both tasks. The sum of
square ratio was extracted for each cluster showing a
correlation and plotted versus symptomatology or PRP 5-
HT levels. A False Discovery Rate analysis was conducted
to correct for multiple comparisons.
Results
Baseline characteristics
The groups did not significantly differ in age and IQ. As
expected, control subjects scored significantly lower on
baseline autistic traits and symptoms of anxiety, obses-
sionality, depression, inattention (childhood) and hyper-
activity (currently and in childhood). There was no
significant difference between groups in inattention scores
currently (Table 1).
Platelet rich plasma serotonin levels
The data was normally distributed for each group, as
assessed by the Shapiro-Wilk test (p > 0.05). No sig-
nificant differences were observed between groups in
mean PRP 5-HT levels (TD mean= 324.1 μg/l, SD=
220.2, ASD mean= 316.1 μg/l, SD= 168.3; t(36)= 0.11,
p= 0.91).
Performance
Go/No-Go task
Multivariate analysis of variance revealed no significant
between-group or within-group differences for the prob-
ability of inhibition or mean reaction time to the Go or
oddball stimuli (Supplementary Table 2).
Sustained attention task
Multivariate analysis of variance revealed significant
differences between TD and ASD during both the placebo
and citalopram conditions on mean reaction time and
coefficient of variation for the 0.5 and 8 s delays. Mean
reaction time was slower and coefficient of variation
higher in ASD compared to controls. For omission errors
there was a significant group difference during the pla-
cebo condition for the 0.5 s delay and for premature
responses, there were significant group differences during
both placebo and citalopram conditions for the 0.5 s delay,
with ASD showing more omission errors and premature
responses. There were no significant within group dif-
ferences in performance outcome following citalopram in
both groups. However, when comparing control subjects
during placebo with ASD cases during citalopram the
group difference of coefficient of variation for the 8 s
delay condition was no longer significant (Supplementary
Table 3).
Visual analogue scales
Despite baseline group differences in associated symp-
tomatology (Table 1), multivariate analysis of variance
showed no significant difference after placebo or citalo-
pram intake in both groups on subjective reports of
physical and psychological symptoms, including palpita-
tions, nausea, dizziness, anxiety, depression or irritability
(Supplementary Table 4).
Table 1 Subjects characteristics
TD
(n= 19a)
ASD (n= 19a) t-test
p-value
Age 27 ± 9
(19–52)
30 ± 11 (19–50) 0.3
IQ 115 ± 10
(88–130)
113 ± 14 (79–139) 0.7
ADOS–Communication – 3 ± 2
ADOS–Social interaction – 6 ± 2
ADI-R–Communication – 17 ± 9
ADI-R–Social interaction – 14 ± 8
ADI-R–Repetitive
behaviour
– 5 ± 2
AQ 12 ± 7 31 ± 11 <0.001***
HAM-D 2 ± 3 6 ± 4 0.001**
HAM-A 3 ± 4 8 ± 6 0.003**
OCI-R 8 ± 9 23 ± 13 <0.001***
GAD-7 3 ± 3 7 ± 5 0.01*
Barkley inattention
childhood self
0.7 ± 1.2 3.3 ± 3.0 0.002**
Barkley hyperactivity
childhood self
1.1 ± 1.9 3.7 ± 2.9 0.004**
Barkley inattention
currently self
0.7 ± 1.5 1.4 ± 1.8 0.2
Barkley hyperactivity
currently self
0.4 ± 0.8 1.2 ± 1.3 0.004**
Data in table is shown as mean ± standard deviation (range) (n= number of
participants)
TD typically developed controls, ASD individuals with autism spectrum disorder,
ADOS Autism diagnostic observation scale, ADI-R Autism diagnostic interview-
revised, AQ Autism quotient, HAM-D Hamilton Depression Rating Scale, HAM-A
Hamilton Anxiety Rating Scale, OCI-R obsessive-compulsive inventory revised
Between group t-test: *= p < 0.05; **= p < 0.01; ***= p < 0.001
an= 19 for Sustained Attention task and n= 17 for Go/No-Go task, which did
not significantly affect between-group differences in baseline characteristics,
platelet rich plasma serotonin (PRP 5-HT) levels or visual analogue scale
measures
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Movement
Go/No-Go task For largest head displacement in three-
dimensional space there was no significant effect of group
(F(1, 64)= 1.13; p= 0.29), drug (F(1, 64)= 2.56; p= 0.11)
or group × drug interaction (F(1, 64)= 0.02; p= 0.89)
(Supplementary Table 5).
Sustained attention task For largest head displacement
in three-dimensional space there was no significant effect
of group (F(1, 72)= 2.3; p= 0.14), drug (F(1, 72)= 1.07;
p= 0.30) or group × drug interaction (F(1, 72)= 0.01; p=
0.92) (Supplementary Table 5).
Within group brain activations The group activation
maps for each group (TD, ASD) and medication (placebo,
citalopram) status revealed significant activation during
successful inhibition (No-Go >Oddball) in response
inhibition regions including inferior, superior and middle
frontal, and pre- and postcentral cortex and cerebellum.
During sustained attention significant activation was
observed in superior and middle frontal, superior and
middle temporal, occipital and pre- and postcentral
cortices and cerebellum (Supplementary Tables 6–13,
Supplementary Figs. 1 and 2).
Group differences in brain activation during placebo and
citalopram
Go/No-Go task
During placebo, subjects with ASD relative to controls
showed a decrease in activation in right postcentral cortex
(p= 0.009, cluster size= 144 voxels). An increase in
activation in ASD compared to controls was observed in
left inferior frontal cortex/left insula (p= 0.02, cluster
size= 95 voxels), right precentral cortex (p= 0.01, cluster
size= 111 voxels), right cerebellum (p= 0.02, cluster size
= 81 voxels) and right occipital cortex (p= 0.01, cluster
size= 114 voxels) (Fig. 1a, Table 2).
Fig. 1 Brain activation map showing abnormally activated regions during response inhibition and sustained attention in ASD that were ‘normalised’
by citalopram; p < 0.02 at cluster level. Location of BOLD signal changes between groups. Red: TD < ASD; Blue: TD > ASD. Numeric label= z Talairach
coordinate. Right hemisphere of brain is on the right side of the image. Abbreviations: BOLD, blood-oxygen-level dependent; TD, Typically Developed
Controls; ASD, Individuals with Autism Spectrum Disorder
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In order to test potential ‘normalisation’ effects, subjects
with ASD during citalopram were compared to controls
during placebo focusing on regions where between-group
differences under placebo were observed. Nearly all
between group differences were no longer observed,
leaving only one small decrease in activation in subjects
with ASD compared to controls in right postcentral cor-
tex (p= 0.005, cluster size= 25 voxels) (Fig. 1b, Table 2).
Subsequently, a within ASD analysis was conducted to
investigate the effect of drug in those regions specifically.
Only the decrease in overactivation of left insula sig-
nificantly ‘normalised’ (p= 0.04, see Fig. 2).
Sustained attention task
During placebo, subjects with ASD relative to controls
showed a decrease in activation in right middle temporal
cortex (p= 0.02, cluster size= 212 voxels), right cuneus
(p= 0.001, cluster size= 1082 voxels) and left precuneus
(p= 0.009, cluster size= 747 voxels) (Fig. 1c, Table 2).
In order to test potential ‘normalisation’ effects, subjects
with ASD during citalopram were compared to controls
during placebo focusing on regions where between-group
differences under placebo were observed. Nearly all
between group differences were no longer observed,
leaving only one small decrease in activation in subjects
with ASD compared to controls in right cuneus (p= 0.03,
cluster size= 129 voxels) (Fig. 1d, Table 2). Subsequently,
a within ASD analysis was conducted to investigate the
effect of drug in those regions specifically. Non of the
regions ‘normalised’ significantly.
Group by drug interaction effects
Go/No-Go task There was a significant interaction effect
of BOLD signal response between drug status (placebo,
citalopram) and group (TD, ASD) in left cerebellum
(posterior lobe, crus I/II; p= 0.01 cluster size= 132
voxels). In this region citalopram decreased brain activa-
tion in the control group but increased brain activation in
ASD (Fig. 3 and Table 2).
Sustained attention task There were no significant
interaction effects of BOLD signal response between drug
status (placebo, citalopram) and group (TD, ASD).
Table 2 Anatomical location and statistics for BOLD
activation
Region X Y Z Cluster
p-value
Cluster size
GO/NO-GO task
TD placebo vs ASD placebo
TD>ASD (blue)
Right postcentral cortex 58 −19 33 0.009 144
TD<ASD (red)
Right cerebellum 29 −67 −40 0.02 81
Right occipital cortex 11 −96 −7 0.01 114
Left inferior frontal
cortex/left insula
−40 19 13 0.02 95
Right precentral cortex 43 −7 50 0.01 111
TD placebo vs ASD citalopram
TD>ASD (blue)
Right postcentral cortex 43 −22 33 0.005 25
Interaction of drug status (placebo, citalopram) by group (TD, ASD)
Left Cerebellum,
Posterior Lobe (Crus I/II)
−22 −81 −33 0.01 132
SUSTAINED ATTENTION task
TD placebo vs ASD placebo
TD>ASD (blue)
Right middle
temporal cortex
61 −7 −7 0.02 212
Right cuneus 14 −93 3 0.0008 1082
Left precuneus −4 −63 46 0.009 747
TD placebo vs ASD citalopram
TD>ASD (blue)
Right Cuneus 14 −93 3 0.03 129
x, y, z= Peak Talairach coordinates
BOLD blood-oxygen-level dependent, TD typically developed controls, ASD
individuals with Autism spectrum disorder
Fig. 2 Significant decrease (‘normalisation’) in brain activation during
response inhibition in left inferior frontal cortex within ASD following
citalopram administration. Abbreviations: SSQ, sum of squares
(statistical measure of BOLD response); *= p < 0.05
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Correlations between functional activations and
symptomatology and peripheral 5-HT within ASD
Go/No-Go task
Within ASD, baseline PRP 5-HT levels correlated
positively with BOLD signal under placebo condition in
the left insula (r= 0.81, p < 0.001, cluster size= 23; at
baseline increased activation in ASD compared to TD;
extending from left inferior frontal cortex). Also, the
degree of BOLD signal change between citalopram and
placebo correlated negatively with PRP 5-HT levels in left
insula (r=−0.8, p < 0.0001, cluster size= 42 voxels; at
baseline increased activation in ASD compared to TD;
extending from left inferior frontal cortex) and positively
in the right postcentral cortex (r= 0.8, p < 0.0001, cluster
size= 52 voxels; at baseline decreased activation in ASD
compared to TD) (Supplementary Fig. 3). Hence, the
higher the individual’s PRP 5-HT levels were at baseline,
the more likely their brain activation in left insula and
right postcentral cortex would ‘normalise’ after
citalopram.
Sustained attention task
Within ASD, ADOS communication scores correlated
negatively with BOLD signal under placebo condition in
right cuneus (r=−0.59, p= 0.01, cluster size= 201; at
baseline decreased activation in ASD compared to TD).
Furthermore, the degree of BOLD signal change between
citalopram and placebo correlated positively with severity
of current hyperactivity symptoms in the right middle
temporal cortex (r= 0.7, p= 0.001, cluster size= 71
voxels; at baseline decreased activation in ASD compared
to TD) and with severity of current inattention symptoms
in the right postcentral cortex (r= 0.7, p= 0.001, cluster
size= 84 voxels; at baseline decreased activation in ASD
compared to TD) (Supplementary Fig. 3). Hence, the
more severe an individual’s hyperactivity or inattention
scores were at baseline, the more likely their brain acti-
vation would ‘normalise’ after citalopram.
No correlations between functional activations and PRP
5-HT levels or symptoms were observed in the TD group.
Discussion
To our knowledge, this is the first fMRI study to
examine the effect of citalopram on brain activation
during EF in adults with ASD. We observed abnormal
brain activation in adults with ASD compared to controls
during successful inhibitory control in left inferior frontal,
right precentral and postcentral cortices, and right cere-
bellum. During sustained attention, we observed reduced
brain activation in ASD compared to controls in the right
middle temporal cortex, right cuneus and left precuneus.
Following citalopram dosing, these atypical brain activa-
tions during both tasks were mostly ‘abolished’ and during
response inhibition ‘normalised’ in left inferior frontal
cortex. Further studies are needed to determine if ‘nor-
malisation’ of brain response during EF tasks is main-
tained by longer term citalopram treatment, and
associated with treatment response.
Fig. 3 Interaction of drug status (placebo, citalopram) by group (TD, ASD) during response inhibition; p < 0.02 at cluster level. Location of BOLD signal
for ANOVA interaction. Numeric label= z Talairach coordinate. Box plots: Mean BOLD signal extracted from each interaction cluster. Right
hemisphere of brain is on the right side of the image. Abbreviations: SSQ, sum of squares fMRI statistic; BOLD, blood-oxygen-level dependent; TD,
Typically Developed Controls; ASD, Individuals with Autism Spectrum Disorder
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The observed group differences under placebo condi-
tion in brain activation during the EF tasks are partially in
line with previous work. For instance, we previously
reported abnormal brain activation during response
inhibition in children with ASD18 and adults with
Asperger’s syndrome19. Both studies reported increased
activation of left inferior frontal cortex, a region that is
critical for successful response inhibition, specifically
motor responses51. Bilateral inferior frontal cortex has
been associated with inhibitory control in fMRI52–54,
lesion55 and transcranial magnetic stimulation (TMS)
studies56,57. However, bilateral inferior frontal cortex has
also been associated with the broader role in target
detection or oddball attention processes that may expe-
dite response inhibition58–60. Likewise, the finding in the
present study of decreased brain activation during sus-
tained attention partially overlaps with our previous stu-
dies of the same task in ASD children20 and a mixture of
children and adults16. In these studies we reported
decreased brain activity in prefrontal, parietal, temporal,
striato-thalamic and cerebellar regions. Thus, our findings
of abnormal brain activation during both tasks support
the suggestion that individuals with ASD have abnorm-
alities in brain activation during EF.
Our finding of ‘normalisation’ in brain function differ-
ences during response inhibition after citalopram is also
in line with a previous fMRI investigation of an acute dose
of fluoxetine in boys with ASD18. Taken together these
studies suggest that SSRIs can modulate abnormal brain
activation in both children and adults with ASD. In
addition, within ASD individuals we observed a strong
association between PRP 5-HT levels and the degree of
‘normalisation’ in left inferior frontal cortex and right
postcentral cortex. In contrast, however, no associations
were observed within the control group. This suggests
that baseline PRP 5-HT levels may underpin brain func-
tional response to citalopram, but specifically in ASD.
However, as we did not include a control group with a
mood or anxiety disorder, we cannot rule out the possi-
bility that this effect may also be present in such
populations.
The ‘abolition’ effect of citalopram on brain function
abnormalities in sustained attention networks in ASD is a
novel finding. Also, the degree of ‘abolition’ after citalo-
pram in right middle temporal and postcentral cortex
correlated with hyperactivity and inattention symptoms,
respectively. In addition, impaired task performance in
ASD compared to controls was no longer significant after
citalopram administration (for coefficient of variation).
Moreover, we observed a significant increase in a self-
reported measure of inattentiveness after citalopram in
the control group, but not in ASD. This suggests that
citalopram improves both attention performance and its
underlying neurofunctional networks in ASD. This could
potentially transfer into clinical improvement of inatten-
tion symptoms, which are also present in frequent
comorbid psychiatric conditions such as ADHD61 and
depression62,63.
Our interaction analysis during response inhibition
revealed that in the left cerebellum (posterior lobe crus I/
II), a region that is involved in cognitive control64,65 and
connected to the frontal cortex66, citalopram shifted brain
activation in the opposite direction in ASD compared to
controls - citalopram decreased brain activation in the
control group, but increased brain activation in ASD. This
“reversal” of brain activation may reflect structural cere-
bellar abnormalities as well as dysfunctions of frontal-
cerebellar networks that have frequently been reported in
ASD populations. For example, abnormalities in struc-
tural white matter connectivity both within the cere-
bellum as well as its cortical and mid-brain projections
have been reported in ASD67,68. Functional connectivity
studies support these findings, suggesting differences in
connections between the cerebellum and both motor and
non-motor regions of the cortex in ASD69,70. This sug-
gests that the neuropharmacological impact of citalopram
is different in ASD than in controls. Therefore, it is pos-
sible that results from treatment studies in typically
developed populations cannot be directly translated to
individuals with ASD. This stresses the need for phar-
macological interventions, affecting the serotonergic sys-
tem, to be tested specifically in ASD.
Our study has a number of limitations. First, we only
included high functioning adult males and therefore
cannot generalise our findings to other groups including
females, children or lower functioning individuals. Sec-
ond, we only used a single dosage of citalopram and we
therefore cannot comment on whether the ‘normalisation’
effects will be maintained by long-term treatments. Third,
for the Go/No-Go task, we did not find any differences in
performance measures. This, however, is in line with a
previous study using the Go/No-Go task35 and possibly
caused by our relatively small sample size, that may be
underpowered for behavioural data. For example, a recent
study using a much larger sample (201 ASD cases and 240
controls) employed an online Go/No-Go task and
reported deficits in response inhibition that was asso-
ciated with diagnosis and autistic traits15. Nevertheless,
our sample was large enough to detect brain activation
differences, which have previously been reported to be
more sensitive to drug effects than behaviour, including in
fMRI studies of ASD34,35. Last, the p-value at cluster level
was set at 0.02, which resulted in less than one false
positive cluster per map for the sustained attention task
but three potentially false positive clusters for the Go/No-
Go task. Therefore, three of the reported regions may be
false-positive clusters. However, we decided to include
them as they overlap with regions previously reported to
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show abnormal activation in ASD population (e.g.
increased activation in left inferior frontal cortex)18,19,35.
In conclusion, we report that, within individuals with
ASD, citalopram can ‘normalise’ brain functional differ-
ences during EF, and these modulations are associated
with PRP 5-HT levels. This suggests a potential utility of
citalopram for targeting EF related problems (e.g. core
symptoms) in ASD. Therefore, future trials should
investigate whether this shift in brain activation after a
single dosage of citalopram is maintained after prolonged
treatment, and whether this is associated with treatment
response. Additionally, further studies are required to
determine whether long-term treatment outcome to
SSRIs is associated with elevated 5-HT levels.
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